Cargando…

Acute and Fatal Isoniazid-Induced Hepatotoxicity: A Case Report and Review of the Literature

This paper describes a case of an acute and fatal isoniazid-induced hepatotoxicity and provides a review of the literature. A 65-year-old female diagnosed with latent Mycobacterium tuberculosis infection was receiving oral isoniazid 300 mg daily. She was admitted to the hospital for epigastric and r...

Descripción completa

Detalles Bibliográficos
Autores principales: Kabbara, Wissam K., Sarkis, Aline T., Saroufim, Paola G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014938/
https://www.ncbi.nlm.nih.gov/pubmed/27648319
http://dx.doi.org/10.1155/2016/3617408
_version_ 1782452348088483840
author Kabbara, Wissam K.
Sarkis, Aline T.
Saroufim, Paola G.
author_facet Kabbara, Wissam K.
Sarkis, Aline T.
Saroufim, Paola G.
author_sort Kabbara, Wissam K.
collection PubMed
description This paper describes a case of an acute and fatal isoniazid-induced hepatotoxicity and provides a review of the literature. A 65-year-old female diagnosed with latent Mycobacterium tuberculosis infection was receiving oral isoniazid 300 mg daily. She was admitted to the hospital for epigastric and right sided flank pain of one-week duration. Laboratory results and imaging confirmed hepatitis. After ruling out all other possible causes, she was diagnosed with isoniazid-induced acute hepatitis (probable association by the Naranjo scale). After discharge, the patient was readmitted and suffered from severe coagulopathy, metabolic acidosis, acute kidney injury, hepatic encephalopathy, and cardiorespiratory arrest necessitating two rounds of cardiopulmonary resuscitation. Despite maximal hemodynamic support, the patient did not survive. A review of the literature, from several European countries and the United States of America, revealed a low incidence of mortality due to isoniazid-induced hepatotoxicity when used as a single agent for latent Mycobacterium tuberculosis infection. As for the management, the first step consists of withdrawing isoniazid and rechallenge is usually discouraged. Few treatment modalities have been proposed; however there is no robust evidence to support any of them. Routine monitoring for hepatotoxicity in patients receiving isoniazid is warranted to prevent morbidity and mortality.
format Online
Article
Text
id pubmed-5014938
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-50149382016-09-19 Acute and Fatal Isoniazid-Induced Hepatotoxicity: A Case Report and Review of the Literature Kabbara, Wissam K. Sarkis, Aline T. Saroufim, Paola G. Case Rep Infect Dis Case Report This paper describes a case of an acute and fatal isoniazid-induced hepatotoxicity and provides a review of the literature. A 65-year-old female diagnosed with latent Mycobacterium tuberculosis infection was receiving oral isoniazid 300 mg daily. She was admitted to the hospital for epigastric and right sided flank pain of one-week duration. Laboratory results and imaging confirmed hepatitis. After ruling out all other possible causes, she was diagnosed with isoniazid-induced acute hepatitis (probable association by the Naranjo scale). After discharge, the patient was readmitted and suffered from severe coagulopathy, metabolic acidosis, acute kidney injury, hepatic encephalopathy, and cardiorespiratory arrest necessitating two rounds of cardiopulmonary resuscitation. Despite maximal hemodynamic support, the patient did not survive. A review of the literature, from several European countries and the United States of America, revealed a low incidence of mortality due to isoniazid-induced hepatotoxicity when used as a single agent for latent Mycobacterium tuberculosis infection. As for the management, the first step consists of withdrawing isoniazid and rechallenge is usually discouraged. Few treatment modalities have been proposed; however there is no robust evidence to support any of them. Routine monitoring for hepatotoxicity in patients receiving isoniazid is warranted to prevent morbidity and mortality. Hindawi Publishing Corporation 2016 2016-08-25 /pmc/articles/PMC5014938/ /pubmed/27648319 http://dx.doi.org/10.1155/2016/3617408 Text en Copyright © 2016 Wissam K. Kabbara et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Kabbara, Wissam K.
Sarkis, Aline T.
Saroufim, Paola G.
Acute and Fatal Isoniazid-Induced Hepatotoxicity: A Case Report and Review of the Literature
title Acute and Fatal Isoniazid-Induced Hepatotoxicity: A Case Report and Review of the Literature
title_full Acute and Fatal Isoniazid-Induced Hepatotoxicity: A Case Report and Review of the Literature
title_fullStr Acute and Fatal Isoniazid-Induced Hepatotoxicity: A Case Report and Review of the Literature
title_full_unstemmed Acute and Fatal Isoniazid-Induced Hepatotoxicity: A Case Report and Review of the Literature
title_short Acute and Fatal Isoniazid-Induced Hepatotoxicity: A Case Report and Review of the Literature
title_sort acute and fatal isoniazid-induced hepatotoxicity: a case report and review of the literature
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014938/
https://www.ncbi.nlm.nih.gov/pubmed/27648319
http://dx.doi.org/10.1155/2016/3617408
work_keys_str_mv AT kabbarawissamk acuteandfatalisoniazidinducedhepatotoxicityacasereportandreviewoftheliterature
AT sarkisalinet acuteandfatalisoniazidinducedhepatotoxicityacasereportandreviewoftheliterature
AT saroufimpaolag acuteandfatalisoniazidinducedhepatotoxicityacasereportandreviewoftheliterature